Sanofi submits new diabetes drug application to US regulator
Paris: French drugmaker Sanofi said it had submitted an application to the US Food and Drug Administration (FDA) for a single daily insulin injection to treat adults with type 2 diabetes.
Sanofi said it had requested a six-month review of its new drug application by the FDA, rather than the standard 10 months.
"A large unmet medical need still exists for people with type 2 diabetes, as more than half are not at their blood sugar goal despite using oral medications or insulin," Sanofi's diabetes head, Pierre Chancel, said in a statement.
The latest application involves a combination of insulin glargine with its lixisenatide drug, Sanofi said.
Sanofi said it had requested a six-month review of its new drug application by the FDA, rather than the standard 10 months.
"A large unmet medical need still exists for people with type 2 diabetes, as more than half are not at their blood sugar goal despite using oral medications or insulin," Sanofi's diabetes head, Pierre Chancel, said in a statement.
The latest application involves a combination of insulin glargine with its lixisenatide drug, Sanofi said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.